NAV

Dexrabeprazole

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Dexrabeprazole is a proton pump inhibitor indicated in the treatment of gastroesophageal reflux disease and gastrointestinal ulcers.

Generic Name
Dexrabeprazole
DrugBank Accession Number
DB13762
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 359.443
Monoisotopic: 359.130362243
Chemical Formula
C18H21N3O3S
Synonyms
  • Rabeprazole, (r)-

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbataceptThe metabolism of Dexrabeprazole can be increased when combined with Abatacept.
AbrocitinibThe metabolism of Abrocitinib can be decreased when combined with Dexrabeprazole.
AcenocoumarolThe metabolism of Dexrabeprazole can be decreased when combined with Acenocoumarol.
AdalimumabThe metabolism of Dexrabeprazole can be increased when combined with Adalimumab.
AlbendazoleThe metabolism of Dexrabeprazole can be decreased when combined with Albendazole.
Alendronic acidThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexrabeprazole.
AlpelisibThe metabolism of Dexrabeprazole can be decreased when combined with Alpelisib.
AmiodaroneThe metabolism of Dexrabeprazole can be decreased when combined with Amiodarone.
AmitriptylineThe metabolism of Dexrabeprazole can be decreased when combined with Amitriptyline.
AmlodipineThe metabolism of Dexrabeprazole can be decreased when combined with Amlodipine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
DEXRIDON MR 30/10 MG KAPSÜL ,30 KAPSÜLDexrabeprazole (10 mg) + Domperidone (30 mg)CapsuleOralCELTİS İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag

Categories

ATC Codes
A02BC07 — Dexrabeprazole
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzimidazoles
Sub Class
Sulfinylbenzimidazoles
Direct Parent
Sulfinylbenzimidazoles
Alternative Parents
Methylpyridines / Alkyl aryl ethers / Benzenoids / Imidazoles / Heteroaromatic compounds / Sulfoxides / Sulfinyl compounds / Dialkyl ethers / Azacyclic compounds / Organonitrogen compounds
show 2 more
Substituents
Alkyl aryl ether / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Dialkyl ether / Ether / Heteroaromatic compound / Hydrocarbon derivative / Imidazole
show 11 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
65JK8810RM
CAS number
177795-60-7
InChI Key
YREYEVIYCVEVJK-RUZDIDTESA-N
InChI
InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)/t25-/m1/s1
IUPAC Name
2-[(R)-[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanesulfinyl]-1H-1,3-benzodiazole
SMILES
COCCCOC1=CC=NC(C[S@@](=O)C2=NC3=CC=CC=C3N2)=C1C

References

General References
  1. TITCK Product Information: RABBY-D (dexrabeprazole sodium) oral enteric coated tablet [Link]
ChemSpider
8082507
BindingDB
50409892
ChEBI
134729
ChEMBL
CHEMBL1615209
ZINC
ZINC000001530935
PDBe Ligand
RZX
PDB Entries
3pgl

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentGastro-esophageal Reflux Disease (GERD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Capsule25 mg
CapsuleOral
Tablet, delayed releaseOral10 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.336 mg/mLALOGPS
logP2.04ALOGPS
logP2.09Chemaxon
logS-3ALOGPS
pKa (Strongest Acidic)9.35Chemaxon
pKa (Strongest Basic)4.24Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area77.1 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity98.07 m3·mol-1Chemaxon
Polarizability39.48 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Enzymes

Details1. Cytochrome P450 2C19
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Lee SJ: Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine. Front Genet. 2013 Feb 1;3:318. doi: 10.3389/fgene.2012.00318. eCollection 2012. [Article]
  2. Acid peptic diseases: pharmacological approach to treatment [File]

Drug created at June 23, 2017 20:48 / Updated at May 22, 2021 06:01